CLRB Quote, Financials, Valuation and Earnings

Seres Therapeutics has a net margin of -- compared to Cellectar Biosciences's net margin of --. Cellectar Biosciences's return on equity of -- beat Seres Therapeutics's return on equity of --.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1582.5%. On the other hand Seres Therapeutics has an analysts' consensus of $3.82 which suggests that it could grow by 418.23%. Given that Cellectar Biosciences has higher upside potential than Seres Therapeutics, analysts believe Cellectar Biosciences is more attractive than Seres Therapeutics.

Cellectar Biosciences has a beta of 0.963, which suggesting that the stock is 3.676% less volatile than S&P 500. In comparison Seres Therapeutics has a beta of 2.186, suggesting its more volatile than the S&P 500 by 118.578%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seres Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Seres Therapeutics pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than Seres Therapeutics quarterly revenues of --. Cellectar Biosciences's net income of -$14.7M is higher than Seres Therapeutics's net income of -$15.6M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Seres Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 730.55x versus 0.93x for Seres Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Cellectar Biosciences's net margin of -49.65%. Cellectar Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1582.5%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Cellectar Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cellectar Biosciences is more attractive than NovaBay Pharmaceuticals.

Cellectar Biosciences has a beta of 0.963, which suggesting that the stock is 3.676% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cellectar Biosciences's net income of -$14.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 730.55x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Cellectar Biosciences's net margin of -2357.27%. Cellectar Biosciences's return on equity of -- beat Palatin Technologies's return on equity of --.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1582.5%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Cellectar Biosciences has higher upside potential than Palatin Technologies, analysts believe Cellectar Biosciences is more attractive than Palatin Technologies.

Cellectar Biosciences has a beta of 0.963, which suggesting that the stock is 3.676% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Cellectar Biosciences's net income of -$14.7M is lower than Palatin Technologies's net income of -$2.4M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 730.55x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Cellectar Biosciences's net margin of --. Cellectar Biosciences's return on equity of -- beat Theriva Biologics's return on equity of --.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1582.5%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 404.2%. Given that Cellectar Biosciences has higher upside potential than Theriva Biologics, analysts believe Cellectar Biosciences is more attractive than Theriva Biologics.

Cellectar Biosciences has a beta of 0.963, which suggesting that the stock is 3.676% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Cellectar Biosciences's net income of -$14.7M is lower than Theriva Biologics's net income of -$4.4M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 730.55x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.